Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betula pendula pollen allergoid, mannan-conjugated, polymerised
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Vaccines & Immunotherapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Betula pendula pollen allergoid, mannan-conjugated, polymerised (also known as MM09) is an innovative allergen immunotherapy (AIT) candidate developed by Inmunotek for the treatment of birch pollen-induced allergic rhinitis and conjunctivitis. The product utilizes a proprietary technology where birch pollen allergens are first polymerised with glutaraldehyde to form allergoids, which significantly reduces their IgE-binding capacity and improves safety by minimizing the risk of systemic allergic reactions. These allergoids are then conjugated to mannan, a polysaccharide derived from *Saccharomyces cerevisiae*. This conjugation allows for targeted delivery to dendritic cells via C-type lectin receptors, specifically the mannose receptor (CD206). This targeting facilitates efficient allergen processing and promotes the induction of T-regulatory cells and the production of protective IgG4 antibodies. This approach is designed to achieve clinical efficacy with a shorter updosing phase and fewer injections compared to conventional AIT.
- Brand names
- Birmann
- Other names
- Mannan-conjugated birch pollen allergoidBirmann BirchPolymerised birch pollen allergoid conjugated to mannan
02
Targets
Bet v 1-specific T-cell receptorMRC1 (Mannose Receptor C-type 1)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on betula pendula pollen allergoid, mannan-conjugated, polymerised.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betula pendula pollen allergoid, mannan-conjugated, polymerised.